InflaRx N.V. Price Chart
InflaRx N.V. IF0.DE Financial and Trading Overview
InflaRx N.V. stock price | 2.94 EUR |
Previous Close | 2.94 EUR |
Open | 2.94 EUR |
Bid | 0 EUR x N/A |
Ask | 0 EUR x N/A |
Day's Range | 2.94 - 2.94 EUR |
52 Week Range | 0.93 - 5.09 EUR |
Volume | 3 EUR |
Avg. Volume | 5.14K EUR |
Market Cap | 129.91M EUR |
Beta (5Y Monthly) | 0.979929 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.21 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
IF0.DE Valuation Measures
Enterprise Value | 127.31M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 1.6746439 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -2.285 |
Trading Information
InflaRx N.V. Stock Price History
Beta (5Y Monthly) | 0.979929 |
52-Week Change | 37.33% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.09 EUR |
52 Week Low | 0.93 EUR |
50-Day Moving Average | 1.69 EUR |
200-Day Moving Average | 2.5 EUR |
IF0.DE Share Statistics
Avg. Volume (3 month) | 5.14K EUR |
Avg. Daily Volume (10-Days) | 6.77K EUR |
Shares Outstanding | 44.2M |
Float | 32.74M |
Short Ratio | N/A |
% Held by Insiders | 13.09% |
% Held by Institutions | 19.32% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -34.64% |
Return on Equity (ttm) | -30.58% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -55712016 EUR |
Net Income Avi to Common (ttm) | -26566414 EUR |
Diluted EPS (ttm) | -1.21 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 5.53M EUR |
Total Cash Per Share (mrq) | 0.12 EUR |
Total Debt (mrq) | 1.26M EUR |
Total Debt/Equity (mrq) | 1.61 EUR |
Current Ratio (mrq) | 11.24 |
Book Value Per Share (mrq) | 1.755 |
Cash Flow Statement
Operating Cash Flow (ttm) | -31400348 EUR |
Levered Free Cash Flow (ttm) | -99100768 EUR |
Profile of InflaRx N.V.
Country | Germany |
State | N/A |
City | Jena |
Address | Winzerlaer Str. 2 |
ZIP | 07745 |
Phone | 49 3641 508 180 |
Website | https://www.inflarx.de |
Industry | |
Sector(s) | |
Full Time Employees | 44 |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Q&A For InflaRx N.V. Stock
What is a current IF0.DE stock price?
InflaRx N.V. IF0.DE stock price today per share is 2.94 EUR.
How to purchase InflaRx N.V. stock?
You can buy IF0.DE shares on the XETRA exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for InflaRx N.V.?
The stock symbol or ticker of InflaRx N.V. is IF0.DE.
How many shares does InflaRx N.V. have in circulation?
The max supply of InflaRx N.V. shares is 44.2M.
What is InflaRx N.V. Price to Earnings Ratio (PE Ratio)?
InflaRx N.V. PE Ratio is now.
What was InflaRx N.V. earnings per share over the trailing 12 months (TTM)?
InflaRx N.V. EPS is -1.21 EUR over the trailing 12 months.